Where does Phanes Therapeutics, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Phanes Therapeutics, Inc. ranks #27,113 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Phanes Therapeutics, Inc. hold?

Phanes Therapeutics, Inc. holds 10 US utility patents granted between 2022 and 2025, spanning 4 technology areas.

What is Phanes Therapeutics, Inc.'s Innovation Score?

Phanes Therapeutics, Inc. has an Innovation Score of 45.3 out of 100 (top 24% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Phanes Therapeutics, Inc. focus on?

Phanes Therapeutics, Inc.'s top technology area is C07K (Peptides) with 10 patents. Grants appear in 4 CPC subclasses total.

Is Phanes Therapeutics, Inc.'s patent grant rate increasing or decreasing?

Insufficient historical data is available to calculate a velocity trend for Phanes Therapeutics, Inc..

What does claim depth mean for Phanes Therapeutics, Inc.'s patents?

Phanes Therapeutics, Inc.'s patents average 16.5 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Phanes Therapeutics, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Phanes Therapeutics, Inc.

USPTO PatentsView assignee record - 10 granted patents across 4 technology areas, recorded in grant years 2022–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07K (Peptides).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Phanes ranks #27,113 of 49,997 tracked US assignees by granted-patent volume, with 10 patents across 4 technology areas.

#27,113
of 49,997 US assignees by volume: Top 24%
by Innovation Score (45.3/100): 16.5
avg claims per patent

USPTO PatentsView assignee plate

Corpus R27113 · US Corporation #27,113 · 10 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-RICH · TYPE-USCORP · SPAN-YRS · BOOK-RICH

GRANTS-MICRO 10 grants
MID-PACK #27,113/49,997
PHOTO-FINISH Performance Solutions
CPC-NARROW C07K · 4 areas
INNOV-PAR 45.3/100
CLAIMS-RICH 16.5 claims/avg
TYPE-USCORP US Corporation
SPAN-YRS 2022–2025 · 4y
BOOK-RICH 9/10 fields

Nearest grant-volume peer: Performance Solutions, LLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
Phanes Therapeutics · this assignee

45
3D Lighting… · lowest

7

What this shows Phanes's Innovation Score is 45.3/100 (top 24% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where Phanes's grants concentrate

Phanes Therapeutics, Inc. is a focused PatentsView assignee: 4 CPC subclasses with 100% of grants classified under C07K (Peptides). Peak complete grant year is 2022 (6 grants) versus a trough of 1 in 2023. By volume, Phanes sits between Performance Solutions, LLC and Piezotech LLC.

Phanes's three-year grant acceleration

Phanes Therapeutics, Inc. shows 9 grants in 2022–2024 against only 0 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Performance Solut…

10
Perlisten Audio

10
Persyst Developme…

10
Phaeton Manufactu…

10
Pi-cardia

10
Piana Nonwovens

10
Pier Tech Systems

10
Piezotech

10
Phanes Therapeuti… ◀

10

What this shows Phanes holds 10 patents at rank #27,150, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Phanes

By rank, the assignees closest to #27,150 in granted patent volume.

Leaders in C07K (Peptides)

Other assignees with the most granted patents in Phanes's primary technology class.

Phanes's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

45 Top 24% higher than 76% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2022–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2022–2019 baseline. Full figures in the table below.

View data table

Phanes Therapeutics, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2022	6	60.0%
2023	1	10.0%
2024	2	20.0%
2025partial year	1	10.0%

Which technologies does Phanes Therapeutics, Inc. patent most?

C07K - Peptides 10

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 9

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 8

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 4

Top 4 of 4 technology areas

Where it ranks

Overall rank by patents

#27,113

of 49,997 tracked assignees

Innovation Score

45.3 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Phanes Therapeutics, Inc.'s patent record in context - here's where to go next.

Phanes Therapeutics, Inc.'s lead technology class is C07K (Peptides), 100% of its portfolio - see every assignee active in that class. Explore C07K
Ranked #27,113 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Phanes Therapeutics, Inc. against Performance Solutions, LLC, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 45.3/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.